Recce Pharmaceuticals
Monday, June 03, 2024
Company Presentation
![Infectious Disease and Vaccines](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_InfectiousDisease_MTC.png)
Company Presentation Theater 2
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development.
![Recce Pharmaceuticals](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1814521-1-JPG.png)
Company Website:
http://www.recce.com.au
Lead Product in Development:
RECCE® 327
Exchange
ASX
Ticker
RCE
Company HQ City
Sydney
Company HQ State
New South Wales
Company HQ Country
Australia
CEO/Top Company Official
James Graham
Development Phase of Primary Product
Phase II
Primary Speaker